146 related articles for article (PubMed ID: 24602192)
1. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
West ES; Williams VL; Morelli JG
Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
4. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
5. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
6. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
7. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
8. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
9. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
10. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
11. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib.
Finelt N; Lulla RR; Melin-Aldana H; Ruth JS; Lin FY; Su JM; Pourciau CY; Hunt RD; Kenner-Bell BM
Pediatr Dermatol; 2017 May; 34(3):337-341. PubMed ID: 28523881
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitor-induced neutrophilic dermatoses: a bitter-"sweet" scenario.
Heymann WR
Skinmed; 2015; 13(2):132-4. PubMed ID: 26137740
[No Abstract] [Full Text] [Related]
13. Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis.
Richarz NA; Puig L; Pérez N; Cuadra-Urteaga J; Elez E; Fernández-Figueras MT
Cancer Biol Ther; 2019; 20(3):237-239. PubMed ID: 30426827
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
15. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
[No Abstract] [Full Text] [Related]
16. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
17. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
Broski SM; Moran EK; Glazebrook KN; Nathan MA
Clin Nucl Med; 2016 Mar; 41(3):e149-51. PubMed ID: 26447389
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib-induced neutrophilic panniculitis in a child undergoing dual BRAF-MEK inhibitor therapy for glioblastoma multiforme.
Young TK; Gutierrez D; Criscito MC; Kim RH; Lakdawala N; Oza VS
Pediatr Dermatol; 2020 Nov; 37(6):1185-1186. PubMed ID: 32869334
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.
Jhaveri KD; Sakhiya V; Fishbane S
JAMA Oncol; 2015 Nov; 1(8):1133-4. PubMed ID: 26182194
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
[Next] [New Search]